| Literature DB >> 31615499 |
Mitsuro Kanda1, Masahiko Koike2, Chie Tanaka2, Daisuke Kobayashi2, Masamichi Hayashi2, Suguru Yamada2, Goro Nakayama2, Kenji Omae3, Yasuhiro Kodera2.
Abstract
BACKGROUND: The global increase in elderly populations is accompanied by an increasing number of candidates for esophagectomy. Here we aimed to determine the postoperative outcomes after subtotal esophagectomy in elderly patients with esophageal cancer.Entities:
Keywords: Elderly; Esophageal cancer; Prognosis; Safety; Subtotal esophagectomy
Mesh:
Year: 2019 PMID: 31615499 PMCID: PMC6792188 DOI: 10.1186/s12893-019-0617-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Fig. 1Study design
Fig. 2(a) Age distribution of patients who underwent subtotal esophagectomy. (b) Incidence of postoperative complications according to age
Patient characteristics before and after propensity score matching
| Characteristic | Unmatched comparison | Matched comparison | ||||
|---|---|---|---|---|---|---|
| Non-elderly group ( | Elderly group ( | Standardized difference | Non-elderly group ( | Elderly group ( | Standardized difference | |
| Sex (male/female) | 314 / 59 | 59 / 9 | 0.016 | 84 / 16 | 42 / 8 | 0.000 |
| Neoadjuvant treatment | ||||||
| Not performed | 149 (40%) | 34 (58%) | 0.359 | 53 (53%) | 29 (58%) | 0.101 |
| Performed | 224 (60%) | 25 (42%) | 47 (47%) | 21 (42%) | ||
| Surgical approach | ||||||
| Open | 346 (93%) | 52 (88%) | 0.158 | 89 (89%) | 45 (90%) | 0.033 |
| Thoracoscopic | 27 (7%) | 7 (12%) | 11 (11%) | 5 (10%) | ||
| Number of field dissected | ||||||
| 2-field dissection | 221 (59%) | 49 (83%) | 0.528 | 78 (78%) | 40 (80%) | 0.049 |
| 3-field dissection | 152 (41%) | 10 (17%) | 22 (22%) | 10 (20%) | ||
| Tumor size (mm), mean ± SD | 35.4 ± 21.6 | 45.2 ± 23.6 | − 0.432 | 38.3 ± 21.0 | 44.1 ± 21.6 | −0.212 |
| T factor | ||||||
| pT0/pTis | 25 (7%) | 2 (3%) | 0.351 | 1 (1%) | 0 | 0.159 |
| pT1 | 157 (42%) | 29 (49%) | 51 (51%) | 27 (54%) | ||
| pT2 | 54 (14%) | 7 (12%) | 11 (11%) | 6 (12%) | ||
| pT3 | 129 (35%) | 21 (36%) | 37 (37%) | 17 (34%) | ||
| pT4 | 8 (2%) | 0 | 0 | 0 | ||
| N factor | ||||||
| pN0 | 172 (46%) | 30 (51%) | 0.242 | 45 (45%) | 25 (50%) | 0.183 |
| pN1 | 102 (27%) | 17 (29%) | 30 (30%) | 15 (30%) | ||
| pN2 | 65 (18%) | 10 (17%) | 20 (20%) | 9 (18%) | ||
| pN3 | 34 (9%) | 2 (3%) | 5 (5%) | 1 (2%) | ||
| TNM stage | ||||||
| 0 | 17 (4%) | 2 (3%) | 0.556 | 1 (1%) | 0 | 0.3000 |
| I | 97 (26%) | 23 (39%) | 36 (36%) | 21 (42%) | ||
| II | 108 (29%) | 10 (17%) | 20 (20%) | 9 (18%) | ||
| III | 103 (28%) | 22 (38%) | 36 (36%) | 19 (38%) | ||
| IV | 48 (13%) | 2 (3%) | 7 (7%) | 1 (2%) | ||
SD, standard deviation
Patients’ demographics and preoperative clinical characteristics
| Characteristic | Non-elderly group ( | Elderly group |
|
|---|---|---|---|
| Age (years), mean ± SD | 65.0 ± 6.9 | 77.2 ± 2.1 | < 0.001 |
| Sex (male/female) | 84 / 16 | 42 / 8 | 1.000 |
| Performance status (0/1) | 99 / 1 | 50 / 0 | 0.367 |
| Comorbidity (%) | |||
| Anya | 28 (28%) | 23 (46%) | 0.030 |
| Cardiovascular diseasea | 10 (10%) | 12 (24%) | 0.026 |
| Respiratory disease | 3 (3%) | 4 (8%) | 0.186 |
| Cerebrovascular disease | 7 (7%) | 4 (8%) | 0.823 |
| Renal dysfunction | 1 (1%) | 2 (4%) | 0.234 |
| Diabetes mellitus | 11 (11%) | 8 (16%) | 0.393 |
| History of cancer (%) | 16 (16%) | 7 (14%) | 0.747 |
| Brinkman index ≥1000 (%) | 31 (31%) | 17 (34%) | 0.711 |
| Excessive alcohol consumption | 57 (57%) | 26 (52%) | 0.562 |
| Body mass index, mean ± SD | 21.0 ± 3.1 | 21.1 ± 2.8 | 0.721 |
| Blood test, median (range) | |||
| Total lymphocyte count (/mm3) | 1600 (500–3400) | 1450 (500–2900) | 0.071 |
| Albumin (g/dl) | 4.1 (3.0–5.0) | 3.9 (2.9–4.9) | 0.092 |
| Cholinesterase (IU/l) | 276 (117–462) | 248 (96–369) | 0.015 |
| Cholesterol (mg/dl) | 188 (101–360) | 184 (118–261) | 0.579 |
| Creatinine (mg/dl) | 0.8 (0.2–1.6) | 0.9 (0.5–1.6) | 0.077 |
| CEA (ng/ml) | 2.5 (0.4–9.5) | 2.5 (0.9–20.1) | 0.987 |
| SCC (ng/ml) | 1.2 (0.3–7.9) | 1.3 (0.5–5.4) | 0.371 |
| PNI, median (range) | 49.5 (34.5–60.0) | 46.3 (35.0–57.5) | 0.019 |
| CONUT score, median (range) | 1 (0–5) | 1 (0–5) | 0.733 |
| Neoadjuvant treatment (%) | 47 (47%) | 21 (42%) | 0.562 |
SD standard deviation, CEA carcinoembryonic antigen, SCC squamous cell carcinoma antigen, PNI prognostic nutritional index, CONUT Controlling Nutritional Status. aHypertension is not included
Intraoperative and pathological characteristics
| Characteristic | Non-elderly group ( | Elderly group |
|
|---|---|---|---|
| Surgical approach | |||
| Open | 89 (89%) | 45 (90%) | 0.851 |
| Thoracoscopic | 11 (11%) | 5 (10%) | |
| Number of field dissected | |||
| 2-field dissection | 78 (78%) | 40 (80%) | 0.777 |
| 3-field dissection | 22 (22%) | 10 (20%) | |
| Reconstruction | |||
| Jejunal flap | 22 (22%) | 10 (20%) | 0.777 |
| Gastric tube | 78 (78%) | 40 (80%) | |
| Operative time (minutes), mean ± SD | 473 ± 111 | 475 ± 122 | 0.889 |
| Intraoperative blood loss (ml), median (range) | 439 (31–1959) | 517 (187–1886) | 0.051 |
| Intraoperative transfusion (%) | 13 (13%) | 13 (26%) | 0.053 |
| Number of dissected lymph nodes mean ± SD | 43.7 ± 14.8 | 40.1 ± 15.8 | 0.097 |
| Histopathologic Type (%) | |||
| Squamous cell carcinoma | 94 | 49 | 0.192 |
| Adenocarcinoma | 2 | 1 | |
| Others | 4 | 0 | |
| Tumor size (mm), mean ± SD | 38.3 ± 21.0 | 44.1 ± 21.6 | 0.141 |
| Multiple lesion (%) | 15 (15%) | 8 (16%) | 0.873 |
| T factor | |||
| pT0/pTis | 1 (1%) | 0 | 0.806 |
| pT1 | 51 (51%) | 27 (54%) | |
| pT2 | 11 (11%) | 6 (12%) | |
| pT3 | 37 (37%) | 17 (34%) | |
| pT4 | 0 | 0 | |
| N factor | |||
| pN0 | 45 (45%) | 25 (50%) | 0.779 |
| pN1 | 30 (30%) | 15 (30%) | |
| pN2 | 20 (20%) | 9 (18%) | |
| pN3 | 5 (5%) | 1 (2%) | |
| TNM stage | |||
| 0 | 1 (1%) | 0 | 0.546 |
| I | 36 (36%) | 21 (42%) | |
| II | 20 (20%) | 9 (18%) | |
| III | 36 (36%) | 19 (38%) | |
| IV | 7 (7%) | 1 (2%) | |
SD, standard deviation
Postoperative course
| Characteristic | Non-elderly group ( | Elderly group ( |
|
|---|---|---|---|
| Postoperative complications (%) | |||
| CD grade 2 or more | 36 (36%) | 22 (44%) | 0.345 |
| CD grade 3 or more | 12 (12%) | 4 (8%) | 0.445 |
| Reoperation (%) | 6 (6%) | 2 (4%) | 0.599 |
| Operative deatha (%) | 0 | 1 (2%) | 0.137 |
| Length of postoperative stay (days), mean ± SD | 28.1 ± 20.5 | 26.0 ± 20.0 | 0.395 |
| Postoperative adjuvant therapy (%) | 12 (12%) | 1 (2%) | 0.022 |
CD Clavien-Dindo classification, SD standard deviation. aDeath within 90 days after surgery
Fig. 3Prognosis of patients who underwent a curative resection for esophageal cancer according to age. (a) Disease-free, (b) disease-specific and (c) overall survival